BLAINJECTIONINJECTABLE9 Generics Approved
Approved
May 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOMACTON (somatropin) is a recombinant human growth hormone (GH) approved in 1995 for multiple pediatric and adult indications including GH deficiency, Turner syndrome, Prader-Willi syndrome, and chronic kidney disease. It works by binding to GH receptors on cells, triggering intracellular signaling that induces production of IGF-1 and other growth-promoting proteins, ultimately stimulating skeletal growth, protein synthesis, and metabolic effects. The drug is administered via injection and represents the standard-of-care therapeutic modality for growth hormone replacement.
$68KPart D
LOE ApproachingDeclining
Minimal commercial momentum with very low Part D spending and approaching LOE, suggesting a mature product with limited growth trajectory and likely smaller commercial team allocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
Started May 2026
36 enrolled
Adult Growth Hormone Deficiency
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
Started Jan 2026
141 enrolled
Small for Gestational Age
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Started Dec 2025
186 enrolled
Turner SyndromeShort Stature Homeobox Gene MutationIdiopathic Short Stature+1 more
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
Started Apr 2025
300 enrolled
Idiopathic Short Stature
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
Started Jul 2024
22 enrolled
Achondroplasia
Worked on ZOMACTON at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.